Relationship between serum RANTES levels and radiological progression in rheumatoid arthritis patients treated with methotrexate

L. Boiardi, P. Macchioni, R. Meliconi, L. Pulsatelli, A. Facchini, C. Salvarani

Research output: Contribution to journalArticle

62 Citations (Scopus)

Abstract

Objective: The aim of this study was to evaluate the relationship between serum chemokines and the clinical and radiological response to a one- year course of methotrexate (MTX) in patients suffering from rheumatoid arthritis (RA). Methods: Twenty out-patients suffering from active RA entered a one-year open prospective study on the effects of low dose MTX therapy. Plain radiographs of the hands and feet were taken at study entry and at the end of the follow-up, and were compared for the number of eroded joints. Serum levels of both C-X-C and C-C chemokines were obtained before the initiation of MTX and after 6 and 12 months of treatment. Results: The levels of serum RANTES before treatment were significantly higher in RA patients than in the controls and returned to normal levels after one year of treatment. Serum levels of the other chemokines were either in the normal range or undetectable. Twelve patients (60%) did not show any new eroded joints at the end of the follow-up period and were considered as radiological responders (RR). Serum levels of GRO-α and RANTES after 6 months of treatment were significantly higher among the patients with radiological progression than in RR patients. Conclusions: We observed high levels of serum RANTES in a series of RA patients during the active stage of the disease. MTX treatment significantly lowered the serum levels of RANTES, GRO- α and MCP-1. High levels of serum RANTES or GRO-α after 6 months of MTX treatment seem to be predictive of radiological erosions after one year.

Original languageEnglish
Pages (from-to)419-425
Number of pages7
JournalClinical and Experimental Rheumatology
Volume17
Issue number4
Publication statusPublished - 1999

Fingerprint

Chemokine CCL5
Methotrexate
Rheumatoid Arthritis
Serum
Chemokines
Therapeutics
Joints
CC Chemokines
Foot
Reference Values
Outpatients
Hand
Prospective Studies

Keywords

  • Methotrexate
  • Rheumatoid arthritis
  • Serum chemokines

ASJC Scopus subject areas

  • Rheumatology
  • Immunology

Cite this

@article{e54116dd3b2c4f66802b295751e12f84,
title = "Relationship between serum RANTES levels and radiological progression in rheumatoid arthritis patients treated with methotrexate",
abstract = "Objective: The aim of this study was to evaluate the relationship between serum chemokines and the clinical and radiological response to a one- year course of methotrexate (MTX) in patients suffering from rheumatoid arthritis (RA). Methods: Twenty out-patients suffering from active RA entered a one-year open prospective study on the effects of low dose MTX therapy. Plain radiographs of the hands and feet were taken at study entry and at the end of the follow-up, and were compared for the number of eroded joints. Serum levels of both C-X-C and C-C chemokines were obtained before the initiation of MTX and after 6 and 12 months of treatment. Results: The levels of serum RANTES before treatment were significantly higher in RA patients than in the controls and returned to normal levels after one year of treatment. Serum levels of the other chemokines were either in the normal range or undetectable. Twelve patients (60{\%}) did not show any new eroded joints at the end of the follow-up period and were considered as radiological responders (RR). Serum levels of GRO-α and RANTES after 6 months of treatment were significantly higher among the patients with radiological progression than in RR patients. Conclusions: We observed high levels of serum RANTES in a series of RA patients during the active stage of the disease. MTX treatment significantly lowered the serum levels of RANTES, GRO- α and MCP-1. High levels of serum RANTES or GRO-α after 6 months of MTX treatment seem to be predictive of radiological erosions after one year.",
keywords = "Methotrexate, Rheumatoid arthritis, Serum chemokines",
author = "L. Boiardi and P. Macchioni and R. Meliconi and L. Pulsatelli and A. Facchini and C. Salvarani",
year = "1999",
language = "English",
volume = "17",
pages = "419--425",
journal = "Clinical and Experimental Rheumatology",
issn = "0392-856X",
publisher = "Clinical and Experimental Rheumatology S.A.S.",
number = "4",

}

TY - JOUR

T1 - Relationship between serum RANTES levels and radiological progression in rheumatoid arthritis patients treated with methotrexate

AU - Boiardi, L.

AU - Macchioni, P.

AU - Meliconi, R.

AU - Pulsatelli, L.

AU - Facchini, A.

AU - Salvarani, C.

PY - 1999

Y1 - 1999

N2 - Objective: The aim of this study was to evaluate the relationship between serum chemokines and the clinical and radiological response to a one- year course of methotrexate (MTX) in patients suffering from rheumatoid arthritis (RA). Methods: Twenty out-patients suffering from active RA entered a one-year open prospective study on the effects of low dose MTX therapy. Plain radiographs of the hands and feet were taken at study entry and at the end of the follow-up, and were compared for the number of eroded joints. Serum levels of both C-X-C and C-C chemokines were obtained before the initiation of MTX and after 6 and 12 months of treatment. Results: The levels of serum RANTES before treatment were significantly higher in RA patients than in the controls and returned to normal levels after one year of treatment. Serum levels of the other chemokines were either in the normal range or undetectable. Twelve patients (60%) did not show any new eroded joints at the end of the follow-up period and were considered as radiological responders (RR). Serum levels of GRO-α and RANTES after 6 months of treatment were significantly higher among the patients with radiological progression than in RR patients. Conclusions: We observed high levels of serum RANTES in a series of RA patients during the active stage of the disease. MTX treatment significantly lowered the serum levels of RANTES, GRO- α and MCP-1. High levels of serum RANTES or GRO-α after 6 months of MTX treatment seem to be predictive of radiological erosions after one year.

AB - Objective: The aim of this study was to evaluate the relationship between serum chemokines and the clinical and radiological response to a one- year course of methotrexate (MTX) in patients suffering from rheumatoid arthritis (RA). Methods: Twenty out-patients suffering from active RA entered a one-year open prospective study on the effects of low dose MTX therapy. Plain radiographs of the hands and feet were taken at study entry and at the end of the follow-up, and were compared for the number of eroded joints. Serum levels of both C-X-C and C-C chemokines were obtained before the initiation of MTX and after 6 and 12 months of treatment. Results: The levels of serum RANTES before treatment were significantly higher in RA patients than in the controls and returned to normal levels after one year of treatment. Serum levels of the other chemokines were either in the normal range or undetectable. Twelve patients (60%) did not show any new eroded joints at the end of the follow-up period and were considered as radiological responders (RR). Serum levels of GRO-α and RANTES after 6 months of treatment were significantly higher among the patients with radiological progression than in RR patients. Conclusions: We observed high levels of serum RANTES in a series of RA patients during the active stage of the disease. MTX treatment significantly lowered the serum levels of RANTES, GRO- α and MCP-1. High levels of serum RANTES or GRO-α after 6 months of MTX treatment seem to be predictive of radiological erosions after one year.

KW - Methotrexate

KW - Rheumatoid arthritis

KW - Serum chemokines

UR - http://www.scopus.com/inward/record.url?scp=0032865441&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032865441&partnerID=8YFLogxK

M3 - Article

C2 - 10464551

AN - SCOPUS:0032865441

VL - 17

SP - 419

EP - 425

JO - Clinical and Experimental Rheumatology

JF - Clinical and Experimental Rheumatology

SN - 0392-856X

IS - 4

ER -